RWE Insights
-
Standardized reporting of cancer recurrence and progression data in registries
Interesting to see the recent publication of a new European expert consensus on the collection of cancer recurrence and progression data by population-based cancer registries. From…
-
A systematic framework for determining lines of therapies (LoT) in solid cancers
In oncology, determining lines of therapy (LoT) has long been a methodological challenge not only in clinical practice, but also in clinical research, health technology assessment, and…
-
Guidance on Post-approval Pregnancy Safety Studies
Last week, the FDA released the updated Guidance on Post-approval Pregnancy Safety Studies (May 2026). Since pregnant individuals are generally excluded from pre-approval clinical trials,…
-
Joint Clinical Assessment (JCA) process
The shift to JCA is starting to reveal a gap between how evidence is planned and what can realistically be delivered under pressure. With uncertainty…
-
Ciencia Research accelerates Nordic real world data access through ethics and governance expertise
Ciencia Research has proven capability to navigate ethics and governance accelerating access to real world data in the Nordics. We recently secured ethics approvals and data…
-
What if you could follow millions of patient journeys?
From diagnosis to treatment to long-term outcomes — using rich, linked health data. At Schain Research, we do exactly that. We specialize in transforming national…
-
Real-World Evidence and the Right to Health: Global Perspectives, Local Impact
Access to high-quality healthcare is not just a goal—it’s a global right. At Schain Research, we believe that robust real-world evidence (RWE) plays a critical…